3 orgs in this cluster's subtree
Every organization with primary activities in Rare Disease Research Funding and Coordination or any of its descendants. Click a column header to sort. Filter by name or state above the table.
| # | Organization | State | Revenue | Activities ↓ |
|---|---|---|---|---|
| 1 | CARDIO-FACIO-CUTANEOUS INTERNATIONAL Nonprofit organization supporting individuals and families affected by Cardio-Facio-Cutaneous (CFC) syndrome, a rare genetic disorder. Provides family support,… | AZ | $146K | 6 |
| 2 | ALPORT SYNDROME FOUNDATION INC The Alport Syndrome Foundation Inc is a nonprofit organization dedicated to supporting individuals affected by Alport syndrome, a rare genetic kidney disease. … | AZ | $991K | 4 |
| 3 | Shay Emma Hammer Research Foundtion The Shay Emma Hammer Research Foundation (SEHRF) funds and conducts translational research to understand the causes of epilepsy, particularly SCN8A-related dis… | AZ | $223K | 2 |
strategies used in this cluster
Theories of action extracted from orgs in this subtree. Click any to see the full set of orgs running the same approach.
- Diagnostic Precision First 1 orgBy improving diagnostic accuracy for genetic syndromes, patients receive appropriate care and support, because precise diagnosis enables correct clinical differentiation from phenotypically similar conditions like Noonan and Costello Syndromes. This strategy prioritizes early and accurate diagnosis as the foundational step to guide effective treatment, research, and support services. It distinguishes itself by focusing on clinical differentiation in the face of symptom overlap, ensuring that patients with rare genetic syndromes like CFC are not misdiagnosed or delayed in accessing tailored interventions. Unlike broader awareness or research funding strategies, this approach targets the diagnostic bottleneck as the critical leverage point for systemic improvement in care pathways.CARDIO-FACIO-CUTANEOUS INTERNATIONAL
- Privacy-Preserving Community Mapping 1 orgBy mapping self-registered, geographically aggregated data with privacy safeguards, increase global visibility of rare disease communities to inform outreach and research, because anonymized spatial data builds trust and enables engagement without risking individual privacy. This strategy enables rare disease organizations to visualize the global distribution of affected families while strictly protecting personal information through aggregation and opt-in participation. Unlike broader data collection approaches, it emphasizes privacy by design, fostering trust within vulnerable communities and supporting ethical research and advocacy planning. It distinguishes itself from other data mapping strategies by prioritizing participant autonomy and confidentiality as foundational to community engagement.CARDIO-FACIO-CUTANEOUS INTERNATIONAL